CA 19-9 방사면역측정법의 기본적 검토 및 악성종양환자에서의 혈청 CA 19-9치의 임상적 의의에 관한 연구 = Performance Characteristics of CA 19-9 Radioimmunoassay and Clinical Significance of Serum CA 19-9 Assay in Patients with Malignancy

다국어 초록 (Multilingual Abstract)

To evaluate the performance characteristics of CA 19-9 radioimmunoassay and the clinical significance of serum CA 19-9 assay in patients with malignancy, serum. CA 19-9 levels were measured by radioimmunoassay using monoclonal antibody in 135 normal controls, 81 patients with various untreated malignancy, 9 patients of postoperative colon cancer without recurrence and 20 patients with benign gastrointestinal diseases, who visited Seoul National University Hospital from June, 1984 to March, 1985.
The results were as follows;
1) The CA 19-9 radioimmunoassay was simple to perform and can be completed in one workd day. And the between-assay reproducibility and the assay recovery were both excellent.
2) The mean serum CA 19-9 level in 135 normal controls was 8.4±4.2U/mL. Normal upper limit of serum CA 19-9 was defined as 21.0U/mL. 4 out of 135 (3.0%) normal controls showed elevated CA 19-9 levels above the normal upper limit.
3) One out of 20 (5.0%) patients with benign gastrointestinal diseases showed elevated srum CA 19-9 level above the normal upper limit.
4) In 81 patients with various untreated malignancy, 41 patients (50.6%) showed elevated serum CA 19-9 levels. 66.7% of 18 patients with colorectal cancer, 100% of 2 patients with pancreatic cancer, 100% of 3 patients with common bile duct cancer, 47.1% of 17 patients with stomach cancer, 28.6% of 28 patients with hepatoma and 60.0% of 5 gastrointestinal tract cancers showed elevated serum CA 19-9 levels.
5) The sensitivities of serum CA 19-9 related to respectability in colorectal and stomach cancer were 33.3% in resectable colorectal cancer, 83.3% in unresectable colorectal cancer, 41.7% in resectable stomach cancer, 60.0% in unresectable stomach cancer respectively.
6) The sensitivity of serum CA 19-9 in 9 patients of postoperative colorectal cancer without recurrence were 33.3% and significantly decressed compared with that of untreated colorectal cancer, 66.7% (p〈0.05).
7) In Patients with colorectal cancer, simultaneous measurement of serum CA 19-9 and seum CEA levels increased sensitivities.
From above results, we concluded that serum CA 19-9 radiommunoassay is simple to perform and reproducible, and is a useful indicator reflecting tumor exent and responses to the treatment in patients with malignancy.